Bank of America has released a new model for AstraZeneca ($AZN), indicating that its earnings per share (EPS) projections are not as high as some other estimates in the market. The model suggests that five Phase 3 readouts scheduled for this year could provide the necessary momentum for the stock. In related biotech news, Akero Therapeutics ($AKRO) is under scrutiny as it prepares for data releases, with expectations of a potential 30% increase or a 70% decrease in stock value based on upcoming Phase 2b trial results. Analysts suggest that if the data shows improvement in fibrosis, there could be up to a 60% upside for $AKRO. Additionally, Eton Pharmaceuticals ($ETNB) is also in focus with three separate Phase 3 trials that could each represent over $1 billion market opportunities in the U.S. alone, as it competes in the same therapeutic space as $AKRO.